Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 1;37(2):67-74.
doi: 10.1097/GCO.0000000000001009. Epub 2025 Jan 13.

Updates in nonhormonal therapy for perimenopausal and menopausal symptoms

Amy J Voedisch  1
Affiliations
Review

Updates in nonhormonal therapy for perimenopausal and menopausal symptoms

Amy J Voedisch. Curr Opin Obstet Gynecol. .

Abstract

Purpose of review: Perimenopausal and menopausal symptoms are common and may significantly impact quality of life. Menopausal hormone therapy is the most effective treatment but may not be appropriate in all cases. Nonhormonal alternatives range from lifestyle changes and dietary supplements to medical interventions and prescription therapies. This review will summarize the newest advancements in nonhormonal therapies for bothersome perimenopausal and menopausal symptoms.

Recent findings: The Menopause Society recently updated their recommendations and guidelines for nonhormonal therapies. Previous recommendations, such as clonidine and pregabalin, are no longer recommended. A new class of medication, neurokinin B antagonists, are now available to target vasomotor symptoms and show promise in addressing sleep and mood issues.

Summary: Well tolerated, effective nonhormonal therapies are available to address perimenopausal and menopausal symptoms for those patients who are not candidates for or chose not to use menopausal hormone therapy.

PubMed Disclaimer

References

    1. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022; 29:767–794.
    1. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause 2023; 30:573–590.
    1. Rees M, Abernethy K, Bachmann G, et al. The essential menopause curriculum for healthcare professionals: a European Menopause and Andropause Society (EMAS) position statement. Maturitas 2022; 158:70–77.
    1. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women’s lives. Am J Med 2005; 118:14–24.
    1. Daley A, Stokes-Lampard H, MacArthur C. Exercise for vasomotor menopausal symptoms. In: The Cochrane Collaboration, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2007, p. CD006108.pub2. https://doi.wiley.com/10.1002/14651858.CD006108.pub2 . [Accessed 11 November 2024]